All In Biotech

Drug Trial Radar · NCT01972529

Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure

A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults With Thrombocytopenia Associated With Liver Disease Prior to an Elective Procedure

Last checked: Nov 20, 2026Latest source record: Feb 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 231 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

231

Actual

Start

Feb 2014

Primary completion

Jan 26, 2017

Study completion Feb 27, 2017

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
Oct 30, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a global, multicenter, randomized, double-blind, placebo-controlled, parallel group study using avatrombopag to treat adults with thrombocytopenia associated with liver disease. The study will evaluate avatrombopag in the treatment of thrombocytopenia associated with liver disease prior to an elective procedure to reduce the need for platelet transfusions or any rescue procedure for bleeding due to procedural and post-procedural bleeding complications. Participants will be enrolled into 2 cohorts according to mean baseline platelet count and, within each baseline platelet count cohort will be further stratified by risk of bleeding associated with the elective procedure (low, moderate, or high) and hepatocellular carcinoma (HCC) status (Yes or No).

Conditions

  • Thrombocytopenia Associated With Liver Disease

Interventions

  • avatrombopag (lower baseline platelet count)Drug

    60 mg avatrombopag (3 x 20 mg tablets)

  • placebo (lower baseline platelet count)Drug

    60 mg placebo (3 x 20 mg matching placebo tablets)

  • avatrombopag (higher baseline platelet count)Drug

    40 mg avatrombopag (2 x 20 mg tablets)

  • placebo (higher baseline platelet count)Drug

    40 mg placebo (2 x 20 mg matching placebo tablets)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Did Not Require a Platelet Transfusion or Any Rescue Procedure for Bleeding After Randomization Following a Scheduled ProcedureTime frame: Baseline (Visit 2) up to 7 days following a scheduled procedure

Locations

109 sites in 20 countries. Site status is shown where the registry gives one.

  • Site not named

    Lancaster, California

  • Site not named

    Long Beach, California

  • Site not named

    Los Angeles, California

  • Site not named

    Sacramento, California

  • Site not named

    San Bernardino, California

  • Site not named

    San Francisco, California

  • Site not named

    Jacksonville, Florida

  • Site not named

    Palmetto Bay, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Rochester, Michigan

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    Jackson, Mississippi

  • Site not named

    New York, New York

  • Site not named

    The Bronx, New York

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Dallas, Texas

  • Site not named

    Harlingen, Texas

  • Site not named

    Houston, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Ciudad Autonoma Buenos Aires, Argentina

  • Site not named

    Mendoza, Argentina

  • Site not named

    Pilar, Buenos Aires, Argentina

  • Site not named

    Camperdown, New South Wales, Australia

  • Site not named

    Adelaide, South Australia, Australia

  • Site not named

    Bedford Park, South Australia, Australia

  • Site not named

    Linz, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Brussels, Belgium

  • Site not named

    Leuven, Belgium

  • Site not named

    São Paulo, Brazil

  • Site not named

    Porto Alegre, Rio Grande do Sul, Brazil

  • Site not named

    São José do Rio Preto, São Paulo, Brazil

  • Site not named

    London, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    La Serena, Chile

  • Site not named

    Santiago, Chile

  • Site not named

    Beijing, China

  • Site not named

    Changsha, Hu'nan, China

Showing 40 of 109 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.